Prof. Dr. Bernd Wullich

Lehrstuhl für Urologie

Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (2019) Weyerer V, Weisser R, Moskalev E, Haller F, Stöhr R, Eckstein M, Zinnall U, et al. Journal article Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution Development and Usability Analysis of a Multimedia eConsent Solution (2019) Schneiderheinze H, Prokosch HU, Apel H, Bellut L, Wullich B, Trollmann R, Schüttler C Book chapter / Article in edited volumes Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (2019) Weyerer V, Weisser R, Moskalev E, Haller F, Stoehr R, Eckstein M, Zinnall U, et al. Journal article Large nested variant of urothelial carcinoma: a prime example of a FGFR3-mutated, luminal tumour (2019) Weyerer V, Eckstein M, Comperat E, Juette H, Allory Y, Stoehr R, Wullich B, et al. Conference contribution Tumour immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes (2019) Eckstein M, Strissel P, Pfannstiel C, Chiappinelli K, Sikic D, Wach S, Taubert H, et al. Conference contribution Treatment of benign prostatic hyperplasia in geriatric patients-use and limitations of existing guidelines (2019) Schoeb DS, Wullich B, Duerschmied D, Heimbach B, Heupel-Reuter M, Gross AJ, Wilhelm K, et al. Journal article Analytical and inter-observer comparability of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry assays in advanced clear cell renal cell carcinoma (CCRCC) (2019) Sommer U, Eckstein M, Ammann J, Braunschweig T, Macher-Goeppinger S, Schwamborn K, Hieke-Schulz S, et al. Conference contribution